Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
JNJ-38518168/ MTX · 1 trial · 1 indication
To assess the effect of multiple doses of JNJ-38518168 on blood levels of methotrexate
| Arm | Type | Description |
|---|---|---|
| 001 | EXPERIMENTAL | JNJ-38518168 / MTX Day 1: MTX: Route=oral use single dose of participant's weekly MTX dose Days 2-15: MTX: Route=oral use single dose of participant's weekly MTX dose and of JNJ-38518168 Type=exact unit=mg number=100 form=capsule route=oral use administered daily. |
| Name | Type | Description |
|---|---|---|
| JNJ-38518168 / MTX | DRUG | Day 1: MTX: Route=oral use, single dose of participant's weekly MTX dose |
Inclusion Criteria: * Have a body mass index (BMI) between 18 and 38 kg/m2 inclusive, and a body weight between 50-110 kg, inclusive * Have a diagnosis of Rheumatoid Arthritis functional class I-III for at least 3 months prior to Screening * Have been treated with and tolerated oral MTX treatment f...
Top 20 of 28 competitors
JNJ-38518168 is an investigational small molecule being studied for the treatment of moderate to severe plaque-type psoriasis and uncontrolled, persistent asthma. It has also been evaluated in clinical trials involving patients with rheumatoid arthritis and hepatic impairment.
JNJ-38518168 is being developed by Johnson & Johnson, a company traded on the New York Stock Exchange under the ticker symbol JNJ.
JNJ-38518168 is in Phase 2 clinical development. It has completed Phase 2 trials in patients with moderate to severe plaque-type psoriasis and in adults with uncontrolled, persistent asthma. The drug remains investigational and is not approved for any use.
JNJ-38518168 has been studied in several completed trials. NCT02295865 evaluated its safety and efficacy in psoriasis. NCT01823016 studied it in adults with uncontrolled, persistent asthma. NCT01450982 examined its effect on methotrexate levels in rheumatoid arthritis, and NCT01863784 assessed its pharmacokinetics in patients with hepatic impairment.
Yes, JNJ-38518168 is also known as Toreforant. In clinical trial NCT02295865, the study of JNJ-38518168 in participants with moderate to severe plaque-type psoriasis, the drug is referred to as Toreforant (JNJ-38518168).
JNJ-38518168 has completed a Phase 2 trial in symptomatic adult participants with uncontrolled, persistent asthma. This trial, NCT01823016, enrolled 166 participants across the United States, Canada, France, Germany, Israel, and the United Kingdom. The trial is completed, and the drug remains investigational.